Advanced

C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register

Pikkemaat, Miriam LU ; Andersson, Tobias; Melander, Olle LU ; Chalmers, John; Rådholm, Karin and Bengtsson Boström, Kristina LU (2019) In Diabetes Research and Clinical Practice 150. p.174-183
Abstract

Aims: To study the association between baseline level of C-peptide and all-cause death, cardiovascular death and cardiovascular complications among persons with newly diagnosed type 2 diabetes. Methods: The Skaraborg Diabetes Register contains data on baseline C-peptide concentrations among 398 persons <65 years with newly diagnosed type 2 diabetes 1996–1998. National registries were used to determine all-cause death, cardiovascular death and incidence of myocardial infarction and ischemic stroke until 31 December 2014. The association between baseline C-peptide and outcomes were evaluated with adjustment for multiple confounders by Cox regression analysis. Missing data were handled by multiple imputation. Results: In the imputed and... (More)

Aims: To study the association between baseline level of C-peptide and all-cause death, cardiovascular death and cardiovascular complications among persons with newly diagnosed type 2 diabetes. Methods: The Skaraborg Diabetes Register contains data on baseline C-peptide concentrations among 398 persons <65 years with newly diagnosed type 2 diabetes 1996–1998. National registries were used to determine all-cause death, cardiovascular death and incidence of myocardial infarction and ischemic stroke until 31 December 2014. The association between baseline C-peptide and outcomes were evaluated with adjustment for multiple confounders by Cox regression analysis. Missing data were handled by multiple imputation. Results: In the imputed and fully adjusted model there was a significant association between 1 nmol/l increase in C-peptide concentration and all-cause death (HR 2.20, 95% CI 1.49–3.25, p < 0.001, number of events = 104), underlying cardiovascular death (HR 2.69, 1.49–4.85, p = 0.001, n = 35) and the composite outcome of underlying cardiovascular death, myocardial infarction or ischemic stroke (HR 1.61, 1.06–2.45, p = 0.027, n = 90). Conclusions: Elevated C-peptide levels at baseline in persons with newly diagnosed type 2 diabetes are associated with increased risk of all-cause and cardiovascular mortality. C-peptide might be used to identify persons at high risk of cardiovascular complications and premature death.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
C-peptide, Cardiovascular diseases, Cause of death, Cohort studies, Mortality, Type 2 diabetes mellitus
in
Diabetes Research and Clinical Practice
volume
150
pages
10 pages
publisher
Elsevier
external identifiers
  • scopus:85063081718
ISSN
0168-8227
DOI
10.1016/j.diabres.2019.03.014
language
English
LU publication?
yes
id
93688e19-89d3-485b-82fa-5bb53c01fcd2
date added to LUP
2019-03-27 13:36:01
date last changed
2019-04-23 04:47:27
@article{93688e19-89d3-485b-82fa-5bb53c01fcd2,
  abstract     = {<p>Aims: To study the association between baseline level of C-peptide and all-cause death, cardiovascular death and cardiovascular complications among persons with newly diagnosed type 2 diabetes. Methods: The Skaraborg Diabetes Register contains data on baseline C-peptide concentrations among 398 persons &lt;65 years with newly diagnosed type 2 diabetes 1996–1998. National registries were used to determine all-cause death, cardiovascular death and incidence of myocardial infarction and ischemic stroke until 31 December 2014. The association between baseline C-peptide and outcomes were evaluated with adjustment for multiple confounders by Cox regression analysis. Missing data were handled by multiple imputation. Results: In the imputed and fully adjusted model there was a significant association between 1 nmol/l increase in C-peptide concentration and all-cause death (HR 2.20, 95% CI 1.49–3.25, p &lt; 0.001, number of events = 104), underlying cardiovascular death (HR 2.69, 1.49–4.85, p = 0.001, n = 35) and the composite outcome of underlying cardiovascular death, myocardial infarction or ischemic stroke (HR 1.61, 1.06–2.45, p = 0.027, n = 90). Conclusions: Elevated C-peptide levels at baseline in persons with newly diagnosed type 2 diabetes are associated with increased risk of all-cause and cardiovascular mortality. C-peptide might be used to identify persons at high risk of cardiovascular complications and premature death.</p>},
  author       = {Pikkemaat, Miriam and Andersson, Tobias and Melander, Olle and Chalmers, John and Rådholm, Karin and Bengtsson Boström, Kristina},
  issn         = {0168-8227},
  keyword      = {C-peptide,Cardiovascular diseases,Cause of death,Cohort studies,Mortality,Type 2 diabetes mellitus},
  language     = {eng},
  pages        = {174--183},
  publisher    = {Elsevier},
  series       = {Diabetes Research and Clinical Practice},
  title        = {C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register},
  url          = {http://dx.doi.org/10.1016/j.diabres.2019.03.014},
  volume       = {150},
  year         = {2019},
}